Technology ID
TAB-1698

Chimeric SHIV Gag Proteins Optimize T-Cell Response Against HIV Gag

E-Numbers
E-241-2001-1
E-304-2007-0
Lead Inventor
Nabel, Gary (NIAID)
Applications
Vaccines­­­
Therapeutic Areas
Infectious Disease
Development Status
Animal (mouse) data available
Lead IC
NIAID
ICs
NIAID
HIV Gag has been included in nearly all HIV vaccines entering clinical trials because of its importance in SIV models and its correlation with protection in HIV-infected long-term non-progressors. However, HIV Gag has proven less immunogenic than Env in phase I clinical trial studies. Through sequence comparison, two regions in HIV Gag have been identified as contributing to the decreased immunogenicity observed for HIV Gag. Replacement of these regions with corresponding SIV sequences significantly increased the resulting T-cell response to HIV Gag in mice. Utilization of these chimera in an HIV vaccine could significantly enhance the overall immunogenicity of the vaccine.
Commercial Applications
HIV vaccine

Licensing Contact:
Finch, Dianca
dianca.finch@nih.gov
Phone: 240-669-5503